問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


China Medical University Hospital (在職)

Division of Neurology

Division of Cardiovascular Diseases

更新時間：2023-09-19

林剛旭Lin, Kang-Hsu
  • Principal Investigator
  • Clinical Trial Experience (year) 12 years 10 個月

  • D15926@mail.cmuh.org.tw

Recruiting Trial

12Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

林剛旭

List

35Cases

2014-02-01 - 2016-01-31

Phase III

Acute Stroke Or Transient IsChemic Attack TReated with Aspirin or Ticagrelor and Patient OutcomES

  • Condition/Disease

    Patients with an acute cerebral ischemic event (minor stroke/high-risk TIA) and high risk of subsequent ischemic stroke, who could be randomised within 24 hours of symptom onset

  • Test Drug

    Ticagrelor

Participate Sites
11Sites

Terminated10Sites

Study ended1Sites

林瑞泰
Kaohsiung Medical Univeristy Chung-Ho Memorial Hospital

Division of Neurology

2018-01-22 - 2019-12-31

Phase III

A Randomized, Double-Blinded, Placebo-Controlled, International, Multicentre, Phase III Study to Investigate the Efficacy and Safety of Ticagrelor and ASA Compared with ASA in the Prevention of Stroke and Death in Patients with Acute Ischaemic Stroke or Transient Ischaemic Attack

  • Condition/Disease

    Acute Ischemic Stroke or Transient ischaemic attack

  • Test Drug

    BRILINTA

Participate Sites
16Sites

Recruiting15Sites

Study ended1Sites

李宗海
Linkou Chang Gung Medical Foundation

Division of Neurology

林秀芬
Kaohsiung Medical Univeristy Chung-Ho Memorial Hospital

Division of Neurology

2013-05-20 - 2018-12-31

Phase III

A multicenter, double-blind, placebo-controlled, randomised, parallel-group phase 3 study to evaluate the safety and efficacy of masitinib in patients with mild to moderate Alzheimer’s disease.

  • Condition/Disease

    mild to moderate Alzheimer’s disease

  • Test Drug

    masitinib

Participate Sites
6Sites

Terminated6Sites

2006-12-18 - 2010-09-07

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
13Sites

Terminated13Sites

2008-12-01 - 2011-11-30

Phase III

A randomised, double-blind, parallel-group placebo-controlled phase Ill study to evaluate the efficacy and safety of desmoteplase in subjects with acute ischemic stroke

  • Condition/Disease

    Ischemic stroke

  • Test Drug

    Desmoteplase

Participate Sites
6Sites

Terminated6Sites

劉景寬
Kaohsiung Medical Univeristy Chung-Ho Memorial Hospital

Division of Neurology

2020-02-01 - 2023-12-15

Phase III

A Phase 3 Global, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of ION-682884 in Patients With Hereditary Transthyretin-Mediated Amyloid Polyneuropathy

  • Condition/Disease

    Hereditary Transthyretin-Mediated Amyloid Polyneuropathy

  • Test Drug

    ION-682884 Injection; Inotersen (ISIS 420915) Injection

Participate Sites
4Sites

Recruiting4Sites

2013-01-01 - 2015-12-31

Phase III

Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 12-Month Trial of Leuco-methylthioninium bis(hydromethanesulfonate) in Subjects with Mild to Moderate Alzheimer's Disease

  • Condition/Disease

    Alzeheimer's Disease

  • Test Drug

    LMTM

Participate Sites
6Sites

Terminated5Sites

Study ended1Sites

楊玉婉
China Medical University Hospital

Division of Neurology

2016-03-07 - 2017-12-31

Phase III

A Phase 3, double-blind, randomized study of RVT-101 versus placebo when added to existing stable donepezil treatment in subjects with mild to moderate Alzheimer’s disease

  • Condition/Disease

    Alzheimer’s disease

  • Test Drug

    RVT-101

Participate Sites
5Sites

Terminated4Sites

2017-06-01 - 2019-12-31

Phase III

A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease

  • Condition/Disease

    Alzheimer's Disease

  • Test Drug

    Elenbecestat (E2609)

Participate Sites
13Sites

Terminated11Sites

胡朝榮
Taipei Medical University-Shuang Ho Hospital,Ministry of Health and Welfare

Division of Neurology

劉景寬
Kaohsiung Municipal Gangshan Hospital

未分科

2017-09-04 - 2020-01-31

Phase I/II

A Phase 1b/2, Multi-Center, Double-Blind (Principal Investigators and Study Subjects Blinded, Sponsor Unblinded), Placebo-Controlled, Randomized, Single-Ascending Dose Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of DS-1040b in Subjects With Acute Ischemic Stroke

  • Condition/Disease

    Acute Ischemic Stroke

  • Test Drug

    DS-1040b

Participate Sites
4Sites

Terminated4Sites

1 2 3 4
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB